Related Experiment Video
Updated: Mar 29, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Chardonnay grape marc/grape seed extract blends improve postprandial triglycerides and/or HDL cholesterol
Fanny Lee1, Torey Arvik2, John W Newman3
1Sonomaceuticals, LLC, Santa Rosa, CA, USA; Department of Nutrition, University of California-Davis, Davis, CA, USA.
Abstract:
Dyslipidemia is a modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Chardonnay marc, the residual by-product of winemaking, is an underutilized agricultural product that remains rich in extractable and non-extractable nutrients, including polyphenolics (e.g., flavan-3-ols) and fiber, which may beneficially influence plasma lipids. This study evaluated whether ingestion of Chardonnay grape seed extract/marc blends could improve plasma lipids in adults with dyslipidemia. We hypothesized that a Chardonnay marc-rich blend (HM) would reduce total cholesterol and LDL-cholesterol (LDL-c), while a Chardonnay seed extract-rich blend (HE) would reduce total cholesterol, LDL-c, and triglycerides, without affecting HDL-cholesterol (HDL-c) or endothelial function. Twenty-four adults with mild dyslipidemia completed a 16-week randomized, double-blind, crossover trial involving three 3-week intervention periods (consuming 1500 mg of HM, HE, or microcrystalline cellulose (MCC)), each followed by a 3-week washout. Systolic blood pressure was significantly lower following HE (118.8 ± 2.8 mmHg) compared to HM (125.6 ± 2.5 mmHg). HDL-c concentrations were higher after HM (56.6 ± 2.6 mg/dL) and MCC (55.7 ± 2.5 mg/dL) compared with HE (52.4 ± 2.5 mg/dL), and the number of large HDL particles was lower following HE (7.1 ± 0.7 µmol/L) compared with MCC (7.7 ± 0.7 µmol/L). Additionally, postprandial triglyceride area under the curve was lower after HM compared with HE. These findings suggest that the broader nutrient complexity of Chardonnay marc may offer pleiotropic benefits for modifiable ASCVD risk factors (ClinicalTrials.gov: NCT03203915).
More Related Videos
14:39Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid Digestion
Bioavailability Study Design: Healthy Subjects Versus Patients
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...